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Probability models are extended for periodic cancer screening trials to model sensitivity when it is
changing with an individual’s age and time spent in the preclinical state. Wu et al. (2005) showed that
sensitivity is monotone increasing with age, but intuitively, sensitivity is also a function of the time one
has spent in the preclinical stage. This allows us to infer sensitivity at a late stage, just before symptoms
manifest. We developed the probability model and applied Bayesian inference to the HIP study group
data. The methodology we developed is also applicable to other kinds of chronic diseases.
Keywords: Periodic screening exam, breast cancer, sensitivity, sojourn time, transition probability,
incidence.
Introduction
denoted by S 0 → S p → S c , corresponding,

Early detection and treatment may be effective
ways to decrease mortality rate from cancer. The
primary technique for early detection is
screening exams. According to a recent report of
the National Institute of Health (NIH 2000),
breast cancer is the most common form of
cancer among women in the United States and
the second leading cause of cancer deaths among
women. In the past four decades, seven major
randomized controlled breast cancer screening
trials have been carried out in North America
and Europe.
In a screening program, a large group of
asymptomatic individuals are enrolled in the
program to detect the presence of a specific
disease. The natural history of the disease for an
individual is assumed to follow a progressive
stochastic model, which consists of three states,

respectively, to the disease-free state; the
preclinical disease state, in which an
asymptomatic individual unknowingly has
disease that the screening exam can detect; and
the clinical state when the disease manifests
itself in clinical symptoms. The sensitivity is the
probability that the screening exam is positive
given that the individual is in the preclinical
stage.
The sojourn time refers to the time
beginning when the disease first develops until
the manifestation of clinical symptoms, that
is ( S c − S p ) . The transition probability into the
preclinical stage is the probability density
function of making transition from the diseasefree to the preclinical state. Knowledge of the
sensitivity of the screening modality is necessary
for evaluating the predictive performance of a
screening exam. The screening sensitivity may
depend on a variety of factors, including age,
position, location and size of the tumor, the
experience of the radiologist, etc. For example,
recent studies indicate that the sensitivity of
mammography increases with age at diagnosis
(Wu et al., 2005; Shapiro et al., 1988; Miller et
al., 1992a, 1992b), attributable to the fact that
breast tissue tends to be more dense and fibrous
in younger women, and more soft and fatty in
older women (Kerlikowske, et al., 1996).
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enter Sp during this interval. The 0-th generation
includes all who enter Sp before the initial
screening exam, and we let t −1 ≡ 0.

In Walter and Day (1983), it was found
that sensitivity is negatively correlated with the
sojourn time, Intuitively, when the tumor cell is
just formed, the sensitivity is very small, while
at the late stage, that is, the preclinical stage
comes to an end and the clinical stage will start
soon, the sensitivity is close to one. In Wu, et al.
(2005), the sensitivity was modeled as a function
of age, while transition probability is agedependent as well. Previous result are extended
by investigating changes in the sensitivity from
simultaneous variation of age and time spent in
the preclinical stage.

For each screening exam, let ni ,t0 be the
total number of individuals in this cohort
examined at the i-th screening, s i ,t0 is the
number of cases detected at the i-th screening
exam, and ri ,t0 is the number of cases diagnosed
in the clinical state Sc within the
interval (t i −1 , t i ) . The latter cases are called
interval cases.
Let Dk ,t0 be the probability that an

The Model
Consider a cohort of initially
asymptomatic individuals who enroll in a
screening program. The sensitivity is denoted by
β(t,s|T), where t is the individual’s age at the
screening exam, s is the time duration that one
has been stayed in the preclinical state, and T
represents the sojourn time in the preclinical
state. Define w(t)dt as the probability of a
transition from S0 to Sp during (t, t+dt). Let q(t)
be the probability density function of the sojourn
time in Sp. Let Q ( z ) =



∞

z

individual will be diagnosed at the k-th
scheduled exam (at which her age is
t k −1 = t 0 + k − 1 ) given that she is already in the
preclinical state. The probability that an
individual in S p is detected at the first scheduled
exam (i.e. k = 1 ) at age t 0 is
t0

∞

0

t0 − x

D1,t0 =  w( x)  q (t ) β (t 0 , t 0 − x | t )dtdx. (1)

q ( x)dx, that is, Q(z)

is the survivor function of the sojourn time in the
preclinical state Sp. Throughout this paper, the
time variable t represents the participating
individual’s age. If random variables T and S are
the duration times in S0 and Sp respectively, then
an individual will enter the clinical state Sc at
age T+S, the probability density function of
(T+S) is

The double integral in equation (1)
arises because she must have entered the
preclinical state S p before t 0 , remained in that
state at least until t 0 , and with the sensitivity
changing with the sojourn time and the time
spent in the preclinical stage, as well as with
age.
Consider an i-th generation individual
who was diagnosed at the k-th screening exam
(1 ≤ i < k ) . There are two possibilities: one is
that she passed her previous (k − i − 1) exams
undetected and had a sojourn time of at least
(t k −1 − x) , where x ∈ (t i −1 , t i ) is her onset of

t

I (t ) =  w( x)q (t − x)dx .
0

I(t) is the observable incidence of clinical cases
if no intervention exists.
Consider a cohort of women in the study
group who are all aged t0 at study entry, and a
protocol for K ordered screening examinations
occurring at ages t 0 < t1 <  < t K −1 , where

the preclinical state S p ; the other possibility is
that she entered S p in the (k-1)-th screening

t i = t 0 + i for annual screening exams. Define

interval (t k − 2 , t k −1 ) . Hence, the probability is

the i-th screening interval as the time interval
between the i-th and the (i+1)-th screening
exams (t i −1 , t i ), i=1, 2,…, K-1.The i-th
generation of individuals consists of those who

298

WU, CARIÑO, & WU

L (⋅ | t 0 ) =

Dk ,t0 =
 k −2

w( x ) 
q (t )  ∏ [1 − β (t j , t j − x | t )  β (tk −1 , t k −1 − x | t ) dtdx


tk −1 − x
i = 0 ti −1
 j =i

k − 2 ti

∞

tk −1

∞

tk − 2

tk −1 − x

+

 w( x ) 

K

∏D
k =1

q (t ) β (tk −1 , t k −1 − x | t ) dtdx,

K

individual enters the state S c at a small age

∏∏ D

interval (t , t + dt ), where t ∈ (t k −1 , t k ) . If this
woman was in the i-th generation, i<k, then she
must have gone through her previous (k-i)
screening exams without being detected, and had
a sojourn time (t-x), where x is her onset age of
the preclinical state S p . Another possibility is

t0

I k ,t0 (t ) =
w( x)q(t − x)(∏ [1 − β (t j , t j − x | t − x)]) (3)
j =i
.
t

dx +  w( x)q(t − x)dx

I k ,t0 =
tk

I k , t0 ( t ) dt =

t k −1
tk − x

 k −1

q ( t )  ∏ [1 − β ( t j , t j − x | t )] dtdx
t k −1 − x
 j=i


  w( x) 
i = 0 ti −1





∞

0

tk

+

r

n

− sk ,t0 − rk ,t0

(7)

where t is an individual’s age at the screening
exam, s is the time one has spent in the
preclinical state, T is the sojourn time in the
preclinical state, and t is the average age at
entry in the whole study group. If
b1 > 0, β (t ) will be a monotone increasing
function of age t.
The transition probability density
function w(t) is the instantaneous probability of
a transition from S0 to Sp. The integral

Therefore, for any k = 1,  , K , the probability
of being incident in the k-th screening interval
(t k −1 , t k ) is

k −1 ti

s

(1 −Dk k,t,0t0 − I kk,t,t00 ) k ,t0

1
s
× ,
1 + exp(−b0 − b1 *(t − t )) T

tk



I

β (t , s | T ) =

k −1

ti −1

k =1

sk ,t0 rk ,t0
k ,t0 k ,t0

The age effect and the time spent in the
preclinical state were modeled in the sensitivity
in the following way. The sensitivity is
associated with age by a logistic link, and it is
associated with the time spent in the preclinical
state by a linear function. Let

and incident at age t. Hence for ∀t ∈ (t k −1 , t k ),

i =0

n k ,t0 − s k ,t0 − rk ,t0

(6)

that she may have entered S p after the k-th exam



r

L=

Let I k ,t0 (t)dt be the probability that an

ti

s

The full likelihood for the study group
across all ages is

(2)

k −1

r

I kk,t,t00 (1 − D k k,t,0t0 − I kk,t,t00 )

(5)

∀k = 2,  , K .

for

s k ,t 0
k , t0

w(t )dt represents a lifetime risk for a healthy

female to transit into the preclinical state.
According to the NCI’s SEER database (Ries et
al. 2002), a woman’s lifetime risk of being
diagnosed with breast cancer is 15.7%, which is
less than a woman’s lifetime risk of entering the
preclinical disease state.

w ( x )[1 − Q ( t k − x )]dx .

t k −1

(4)
The likelihood function for this cohort of women
is
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Table 1. Bayesian posterior estimates for the HIP data
Parameters
Median
Mean
S.E.
b0
1.730
1.708
0.984

b1

0.084
0.083
0.072
μ
4.384
4.392
0.065
2
σ
0.235
0.253
0.095
κ
1.744
2.126
1.004
ρ
0.381
0.366
0.104
_______________________________________________________________
Table 2. Bayesian posterior estimates for the sensitivity β at the end of the preclinical state
Age
Median
Mean
S.E.
40
0.644
0.628
0.215
45
0.736
0.716
0.178
50
0.829
0.789
0.150
55
0.886
0.841
0.129
60
0.917
0.877
0.115
65
0.940
0.899
0.109
_____________________________________________
Table 3. Bayesian posterior estimates for the transition probability a w .
Age
Median
Mean
S.E.
40
1.400
1.407
0.243
45
1.734
1.738
0.210
50
1.994
2.006
0.254
55
2.171
2.193
0.335
60
2.267
2.296
0.404
65
2.286
2.322
0.441
_____________________________________________________
a
The unit is 10 −3 .
Hence, 20% is chosen as a reasonable
upper bound.

w(t ) =

0 .2

σt 2π

exp{−

(log t − μ ) 2
}
2σ 2

κx κ −1 ρ κ
q ( x) =
, x > 0,
[1 + ( xρ ) κ ] 2

(9)

where x is the sojourn time, and κ and ρ are
positive parameters representing the scale and
location in the log logistic family. An advantage
of this family over the exponential is that it has
two parameters and is more robust in the tails.

(8)

which is the PDF of lognormal(μ, σ2) multiplied
by 20%. Here, w(t) is a sub-density function,
where μ and σ2 are parameters to be estimated.
The log logistic distribution is adopted
to model the sojourn time in the preclinical state,
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Figure 1: Density Curve for the posterior samples.
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Figure 2: Posterior quantiles (5%, 50%, and 95%) of sensitivity and transition probability.
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parameter vector θ. Sixteen chains were
simulated, each with different starting values
that are over dispersed with respect to the target
distribution. The two-dimensional integrals in
the likelihood function are very time consuming.
The chains were simulated in parallel on a Linux
cluster, taking 192 hours to complete. The 80
posterior samples from each of the 16 chains
were pooled for the analysis, giving a total of
1280 posterior samples.
The Bayesian posterior estimates of θ
for the HIP study data are shown in Table 1.
Sensitivity at the end of the preclinical state
appears to increase with age. If s → T , that is, if
the time spent in the preclinical state s converges
to the sojourn time T, then the sensitivity in the
late stage of the preclinical state can be
estimated. This trend is obvious from the
quantile plot of the saved posterior samples of
the parameters in Figure 1. In the HIP data, the
posterior mean sensitivity increases from 0.628
to 0.899 from ages 40 to 65 years, and the
posterior standard error drops from 0.215 to
0.109. In fact, the posterior error of sensitivity
was monotone decreasing as age increases.
The age-dependent transition probability
is itself a sub-pdf from our model construction.
The posterior density curve of the transition
probability could be seen from Figure 1. The
posterior mean of the transition probability
varies from 1.407 × 10−3 to 2.322 × 10−3 . The
transition probability is not a monotone function
of age; it has a single maximum at age 64. If the
posterior means for the parameters κ and ρ were
used, then the posterior mean sojourn time is
4.06 years, with a mode of 1.70 years.

Another advantage of this family is that its
relatively simple form is achieved for the
survivor function and the hazard function. Its
first moment can be calculated directly from

E( X ) =

π
π 
csc . For the r-th moment to
ρκ  κ 

exist, κ > r is required. For justifications on
how these age effect functions are chosen, see
Wu, et al. (2005).
Simulation Procedure and Results
The analysis of the HIP study data is
now described based on the likelihood function
and probability calculation derived above. In the
proposed model, there are six unknown
parameters, that is, θ = (b0 , b1 , μ , σ 2 , κ , ρ ).
Theoretically, the parameters have a domain of
either (−∞, ∞) or (0, ∞) . The practical
meaning of these parameters will limit them to a
finite range. The range for each of them was
identified as: 0 < b0 < 5 , − 0.2 < b1 < 0.2 ,

3.5 < μ < 4.5 , 0 < σ 2 < 1 , 0.1 < ρ < 2.0 ,
and 1 < κ < 5 . For justifications of these

ranges, see Wu, et al. (2005).
Markov Chain Monte Carlo (MCMC)
was used to generate a random sample from the
joint posterior distribution of the parameters for
Bayesian inference. The posterior simulation
was partitioned into four sub-chains, sampling
the
posterior
for
2
(b0 , b1 ), μ , σ , (κ , ρ ) separately.
A noninformative bivariate normal prior
for (b0 , b1 ) was chosen, that is, a bivariate
normal distribution with mean vector (0,0) and
variance equal to 1010 times the identity matrix.
A noninformative normal prior was chosen
for μ , namely N (0,1010 ) . The prior for σ 2 was
uniform (0, 1), and the prior distributions for κ
and ρ were uniform (1, 5) and uniform (0, 2),
respectively. The two-dimensional integrals in
the likelihood function do not have an analytical
form. The trapezoidal rule was used to evaluate
them when calculating the likelihood.
The MCMC was run for 4,800 steps,
with a burn-in of 3,200 iterations. After the
burn-in time, the posteriors were sampled every
20 steps, giving 80 posterior samples for the

Discussion
The previous model in Wu, et al. (2005) is
extended by adding one element in the
sensitivity function, namely, the time spent in
the preclinical state, with the sojourn time.
Walter and Day (1983) found that the sensitivity
and the sojourn time distribution were
negatively correlated for a given incidence. Our
modeling should be able to handle that problem,
as our sensitivity was defined as a function of
the sojourn time as well, and it was reciprocal to
the sojourn time. More complicated models
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could be explored, but the computation time will
be greatly increased, and simulation would take
too long to be finished.
The result was compared with Wu, et al.
(2005). It was found that the late stage
sensitivity was slightly higher, with a slightly
smaller standard error. It was also found that the
transition probability was changing less across
different ages, with a slightly smaller standard
error. However, the mean sojourn time is much
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